SMALL CELL LUNG CANCER | Clinical

January 19, 2023

Gene G. Finley, MD, discusses how he envisions the treatment landscape of small cell lung cancer may evolve over the next 5-10 years.

January 12, 2023

JBI-802, which is being evaluated in a phase 1/2 trial, received an orphan drug designation from the FDA for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

January 09, 2023

A phase 2 dose expansion cohort which received the investigational agent abequolixron plus docetaxel showed clinical responses in patients with non–small cell lung cancer and small cell lung cancer.

January 09, 2023

Patients with small cell lung cancer will receive diagnostic and post-progression tumor tissue profiling, plasma ctDNA biomarker profiling, standard of care therapy, and disease surveillance in the Sculptor study.

December 14, 2022

Kartik Konduri, MD discussed treatment options for extensive-stage small cell lung cancer during a live virtual event.

November 30, 2022

Gene G. Finley, MD, discusses some of the challenges seen when treating patients with small cell lung cancer.

November 18, 2022

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of patients with extensive-stage small cell lung cancer experiencing chemotherapy-induced myelosuppression events.

November 17, 2022

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

November 16, 2022

Gene G. Finley, MD, discusses the potential use of molecular testing to improve outcomes for patients with relapsed small cell lung cancer.

October 31, 2022

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.